14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYRE vs MDGL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Madrigal Pharmaceuticals, Inc. (MDGL) on higher Unified Composite conviction (36.1/100 SELL vs. 54.0/100 HOLD) after splitting the core matrix 3–7 (led by Profitability & Quality), while MDGL wins 4–1 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.97 (N/M Forward P/E, 0.0% operating margin) versus MDGL at $423.54 (38.1x Forward P/E, -10.7% operating margin).
Composite vs. Pillar Nuance: While MDGL currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (3–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.7% operating margin) and revenue trajectory (+0.0% vs. +50.1% YoY).
Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile MDGL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs MDGL. Trailing 12-month operating profitability (SYRE 0.0% vs MDGL -10.7%) and valuation multiples (SYRE N/M vs MDGL 38.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $9.8B market capitalization and -10.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SYRE vs MDGL Key Questions & Quantitative Answers
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Madrigal Pharmaceuticals, Inc. (MDGL) on higher Unified Composite conviction (36.1/100 SELL vs. 54.0/100 HOLD) after splitting the core matrix 3–7 (led by Profitability & Quality), while MDGL wins 4–1 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.97 (N/M Forward P/E, 0.0% operating margin) versus MDGL at $423.54 (38.1x Forward P/E, -10.7% operating margin). Composite vs. Pillar Nuance: While MDGL currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (3–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.7% operating margin) and revenue trajectory (+0.0% vs. +50.1% YoY). Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile MDGL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MDGL leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MDGL at +50.1% YoY revenue growth and +0.0% YoY earnings growth on $1.43B TTM revenue (91.0% gross margin, -10.7% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $1.43B for MDGL. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MDGL.
MDGL screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MDGL trades at 38.1x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-11.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus MDGL (-24.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, MDGL carries 59.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 0.28x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 49% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.